A BCG Alternative in Bladder Cancer: The Tokyo-172 Strain Is Clinically Equivalent
In this article
The Tokyo-172 Strain Is Becoming an Alternative to Standard BCG Treatment in Bladder Cancer
SWOG S-1602 Phase 3 Analysis: The Tokyo-172 strain is not inferior to TICE; a solution to the global supply crisis is on the horizon.
Intravesical BCG therapy, used to prevent recurrence in patients with non-muscle-invasive bladder cancer (NMIBC), has faced a serious supply problem for years. While access to the currently standard TICE strain remains limited, the SWOG S-1602 study demonstrated that the Japanese Tokyo-172 strain is at least as effective as TICE. This represents a major step toward uninterrupted access to treatment for patients.
Tokyo-172 and TICE: Success Head to Head
In a study involving a thousand patients with a median follow-up of 4.6 years, the Tokyo-172 strain was found noninferior to standard treatment (TICE) in preventing recurrence. Lead investigator Dr. Robert S. Svatek emphasized that the genetic codes and clinical effects of the two strains were very similar.
Another focus of the study was the “priming” strategy: an intradermal injection in the shoulder before surgery intended to enhance the effect of intravesical treatment. It did not provide additional benefit in patients receiving full-dose treatment.
5-Year Survival Success in Numbers
This success with the Tokyo-172 strain shows even greater clinical resistance than the 58% rate achieved with the TICE strain.
The 5-year progression-free survival (PFS) rate was exactly the same for both strains at 79%, reinforcing confidence.
In light of these data, approval of Tokyo-172 is the most realistic solution for easing the worldwide BCG shortage.
Access to Treatment Is the First Step Toward Healing
The unavailability of BCG, our most effective weapon for preventing bladder cancer recurrence, was a major source of stress for patients and for us as physicians. The SWOG S-1602 study gives us breathing room by saying, “There is another option.” The success of the Tokyo-172 strain means more than a drug approval: it means that thousands of patients’ treatments will not be left unfinished.
Science sometimes saves lives not by inventing a new molecule, but by optimizing the resources at hand to address global crises. This study is one of the finest examples of sustainability in oncology.
Scientific References
- 1. Svatek RS, et al. SWOG S-1602 Analysis: Tokyo-172 Strain of BCG Is Noninferior to TICE Strain in NMIBC. ASCO Daily News, Feb 2026 (LBA629).
- 2. Phase 3 SWOG S-1602: Comparing Efficacy of Tokyo vs TICE strains of BCG in High-Risk Bladder Cancer.
- 3. Harvey M, Jack G. Global BCG Shortages and the Impact on Bladder Cancer Care. World J Surg Surgical Res.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.